Search research articles
Contact Us
Filters
Showing results (111-120 of 185) with videos related to
Page
of 19
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
June 10, 2023
Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition
Robert Ferguson, Vylyny Chat, Leah Morales, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Funda Meric-Bernstam, Randy F Sweis, F Stephen Hodi, et al.
Cancer
|
October 5, 2017
First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors
Philippe L Bédard, Michael A Davies, Scott Kopetz, et al.
Journal of Translational Medicine
|
May 10, 2022
The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021
Paolo A Ascierto, Allison Betof Warner, Christian Blank, et al.
Biorxiv : the Preprint Server for Biology
|
September 4, 2023
Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma
Ryan C Augustin, Sarah Newman, Aofei Li, et al.
Journal of Translational Medicine
|
April 18, 2023
The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022
Paolo A Ascierto, Christian Blank, Alexander M Eggermont, et al.
Melanoma Research
|
November 10, 2020
Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target
Riyue Bao, Oliver Surriga, Daniel J Olson, et al.
Cancer Discovery
|
July 30, 2021
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma
Antoni Ribas, Theresa Medina, John M Kirkwood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 2, 2022
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Diwakar Davar, Roberta Zappasodi, Hong Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2025
IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma
David H Aggen, Meredith McKean, Jean H Hoffman-Censits, et al.
Page
of 19
Search research articles
Search
Showing results (111-120 of 185) with videos related to
Sort By:
Page
of 19
European Journal of Cancer (Oxford, England : 1990)
|
June 10, 2023
Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition
Robert Ferguson, Vylyny Chat, Leah Morales, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Funda Meric-Bernstam, Randy F Sweis, F Stephen Hodi, et al.
Cancer
|
October 5, 2017
First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors
Philippe L Bédard, Michael A Davies, Scott Kopetz, et al.
Journal of Translational Medicine
|
May 10, 2022
The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021
Paolo A Ascierto, Allison Betof Warner, Christian Blank, et al.
Biorxiv : the Preprint Server for Biology
|
September 4, 2023
Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma
Ryan C Augustin, Sarah Newman, Aofei Li, et al.
Journal of Translational Medicine
|
April 18, 2023
The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022
Paolo A Ascierto, Christian Blank, Alexander M Eggermont, et al.
Melanoma Research
|
November 10, 2020
Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target
Riyue Bao, Oliver Surriga, Daniel J Olson, et al.
Cancer Discovery
|
July 30, 2021
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma
Antoni Ribas, Theresa Medina, John M Kirkwood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 2, 2022
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Diwakar Davar, Roberta Zappasodi, Hong Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2025
IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma
David H Aggen, Meredith McKean, Jean H Hoffman-Censits, et al.
Page
of 19